NCT01559727

Dose-comparison Study of Prednisone in Heart Failure

Randomized Dose-comparison Study of Prednisone in Patients With Symptomatic Heart Failure

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Hebei Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to examine the efficacy of three doses of prednisone, a glucocorticoid, in treatment of patients with symptomatic heart failure.

Detailed description

Heart failure is a leading cause of cardiovascular morbidity and mortality in the world. Most patients with acute symptomatic heart failure are admitted with fluid overload. Intravenous loop diuretics are an essential component of current treatment in such patients. Newly emerging evidence showed that glucocorticoids could potentiate natriuretic peptides' action by upregulating the expression natriuretic peptide receptor A (NPR-A) in the kidney, and produce a potent diuresis. Therefore, the investigators designed this nonblinded, randomized dose comparison study to compare the efficacy of prednisone at 15, 30 and 60 mg/day in patients with in symptomatic heart failure.

Conditions

• Heart Failure

Interventions

Type	Name	Description
DRUG	prednisone	The patients with symptomatic heart failure are treated with prednisone at dose of 15 mg/day.
DRUG	prednisone	The patients with symptomatic heart failure are treated with prednisone at dose of 30 mg/day
DRUG	prednisone	The patients with symptomatic heart failure are treated with prednisone at dose of 60 mg/day

Timeline

• Start date: 2012-03-01
• Primary completion: 2013-01-01
• Completion: 2013-03-01
• First posted: 2012-03-21
• Last updated: 2013-08-28

Locations

2 sites across 1 country: China